AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
13.62
-0.59 (-4.15%)
At close: Mar 6, 2026, 4:00 PM EST
13.53
-0.09 (-0.66%)
After-hours: Mar 6, 2026, 4:02 PM EST
AgomAb Therapeutics NV Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for AgomAb Therapeutics NV stock have an average target of 32, with a low estimate of 28 and a high estimate of 36. The average target predicts an increase of 134.95% from the current stock price of 13.62.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AgomAb Therapeutics NV stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 |
|---|---|
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $36 | Buy | Initiates | $36 | +164.32% | Mar 3, 2026 |
| JP Morgan | JP Morgan | Buy Initiates $32 | Buy | Initiates | $32 | +134.95% | Mar 3, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $28 | Buy | Initiates | $28 | +105.58% | Mar 3, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.